CRISPR and Genetic Engineering · Journal article

CRISPR-Based Gene Editing in Human and Animal Health: Revolutionizing Disease Resistance and Treatment

Journal of Pure and Applied Microbiology · September 1, 2026

Hypothesis-Generating Why this matters to you Expert discussion

Raises a question worth testing. It does not answer one.

AI Summary

This is a narrative review of CRISPR technology and its potential applications across medicine, agriculture, and veterinary science. It identifies opportunities (genetic disorder treatment, disease-resistant crops, cancer immunotherapy) and barriers (ethical concerns, regulatory fragmentation, cost, equity) but does not present original research, trial data, or quantified clinical outcomes to support any specific therapeutic claim.

What was studied

Journal article.

Key findings

CRISPR described as offering precise modifications for treating sickle cell anemia and Duchenne muscular dystrophy Technology positioned as advancing cancer immunotherapies and antiviral therapies for HIV and COVID-19 Emerging innovations including base editing, prime editing, and epigenetic modifications proposed as solutions to improve precision and safety

Safety

Emerging innovations including base editing, prime editing, and epigenetic modifications proposed as solutions to improve precision and safety

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is a narrative review or position paper discussing CRISPR applications across multiple domains without reporting original experimental data, efficacy comparisons, or clinical trial results.

Caveats

No efficacy data, effect sizes, or clinical trial results reported for any CRISPR application.
No quantitative comparison between CRISPR and standard treatments or between editing modalities.
Descriptions of applications (sickle cell, DMD, HIV, COVID-19) are illustrative only; actual outcomes not specified.
Review does not distinguish between preclinical work, early trials, and established clinical use.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

No empirical study design; text is a thematic review without experimental methodology.

Directness

limited

Discusses potential and promise of CRISPR; no direct clinical or comparative evidence presented.

Consistency

insufficient

Source does not report or compare multiple studies or datasets.

Risk of bias

insufficient

No original data collection or analysis; bias assessment not applicable to narrative review.

Sample adequacy

insufficient

No study population or sample; text is conceptual rather than empirical.

What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.

Source abstract

CRISPR gene-editing technology has revolutionized modern genetics, offering precise and efficient modifications across multiple domains, including human medicine, agriculture, and veterinary science. This study explores the diverse applications of CRISPR, highlighting its role in treating genetic disorders such as sickle cell anemia and Duchenne muscular dystrophy, advancing cancer immunotherapies, and developing CRISPR-based antiviral therapies for HIV and COVID-19. In agriculture, CRISPR has facilitated the development of disease-resistant livestock, enhanced crop yields, and improved food sustainability. Additionally, CRISPR is being integrated with artificial intelligence (AI) and bioinformatics to optimize gene-editing accuracy, predict off-target effects, and accelerate drug discovery. Despite these advancements, CRISPR faces significant challenges, including ethical dilemmas surrounding germline editing, regulatory inconsistencies across countries, high costs of gene therapies, and concerns about genetic inequality. The legal and social implications of CRISPR remain complex, requiring global cooperation to establish standardized regulations and ensure equitable access to genetic therapies. Emerging innovations such as base editing, prime editing, and epigenetic modifications offer promising solutions to improve CRISPR’s precision and safety. Looking ahead, CRISPR’s long-term success will depend on responsible scientific advancements, ethical oversight, and public acceptance. With the continued refinement of gene-editing techniques and AI-driven CRISPR optimizations, this technology holds the potential to revolutionize medicine, agriculture, and environmental conservation. However, careful implementation and transparent discussions are essential to navigate the ethical, legal, and societal challenges that accompany CRISPR’s rapid development.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

CRISPR and Genetic EngineeringBandar Hamad Aloufi